Clinical trials: Myocardial Perfusion
Myocardial Perfusion Imaging, Magnetic Resonance Imaging
Myocardial Perfusion MRI
The object of this study is to compare four different dosages of Gadavist 1.0 in cardiac Magnetic Resonance Tomography (MRT) imaging with the imaging results of a cardiac SPECT examination in terms of diagnostic quality.
- Trial name
- NCT01490294
- Testing
- Gadobutrol (Gadavist,Gadovist, BAY86-4875)
- Where
- 14 sites in Austria, Germany and 2 more
- Volunteers
- 232 people
- Sponsor
- Bayer
Chest Pain
Low Dose One-Day Tc99m Protocol With a High-Efficiency Cardiac Dedicated Gamma Camera For Detection of Coronary Disease
A prospective single clinical trial to validate the use of a low-dose (~5mSv) Tc-99m protocol with a high-efficiency cardiac dedicated camera (Dynamic Single Photon Emission Computed Tomography; D-SPECT) to detect myocardial…
- Trial name
- NCT01135095
- Testing
- low-dose imaging
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Spectrum Dynamics
Coronary Artery Disease (CAD), Ischemic Heart Disease
A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes
This was a Phase 2 prospective, randomized, crossover study of Flurpiridaz (18F) Injection for PET-MPI in participants referred for evaluation of known coronary artery disease (CAD) or for suspected CAD with intermediate to high…
- Trial name
- NCT04594941
- Testing
- Flurpiridaz (18F) Injection
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- GE Healthcare
Coronary Artery Disease
Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI
The study will evaluate the use of Flurpiridaz F18 injection in patients with CAD to determine if the study drug in PET imaging is better than SPECT imaging currently used for this purpose.
- Trial name
- NCT01681524
- Testing
- Flurpiridaz F18
- Sponsor
- Lantheus Medical Imaging
Coronary Artery Disease
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease
This trial is to compare PB127 echocardiography to other heart imaging studies.
- Trial name
- NCT00595244
- Testing
- PB127 for injectable suspension
- Where
- 15 sites in United States
- Volunteers
- 456 people
- Sponsor
- Point Biomedical
Kawasaki Disease
A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease
Determine the predictive value of CARDIOLITE® rest and stress myocardial perfusion imaging (MPI) to define a pediatric population with Kawasaki Disease (KD) at high and low risk of developing cardiac events.
- Trial name
- NCT00162032
- Testing
- Sestamibi
- Where
- 50 sites in United States, Brazil and 5 more
- Volunteers
- 445 people
- Sponsor
- Lantheus Medical Imaging
Coronary Artery Disease
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
- Trial name
- NCT00208312
- Testing
- Regadenoson, Adenosine
- Where
- United States
- Volunteers
- 787 people
- Sponsor
- Gilead Sciences
Coronary Artery Disease, Chest Pain
Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)
To validate the use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood assay in subjects who are referred for the work-up of coronary artery disease.
- Conditions
- Coronary Artery Disease, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease
- Trial name
- COMPASS (NCT01117506)
- Testing
- Corus CAD (ASGES)
- Where
- 7 sites in United States
- Volunteers
- 581 people
- Sponsor
- CardioDx
Coronary Artery Disease (CAD)
Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI
- Trial name
- NCT00826280
- Testing
- regadenoson, overencapsulated caffeine, technetium
- Where
- 25 sites in United States
- Volunteers
- 347 people
- Sponsor
- Astellas Pharma Inc
Cardiovascular Disease, Ischemic Heart Disease
A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging
The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.
- Trial name
- NCT00162071
- Testing
- apadenoson
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Forest Laboratories
Coronary Artery Disease
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The purpose of this study is to see whether apadenoson is as effective as adenosine when used as a pharmacological stress agent in myocardial SPECT-Imaging to detect defects in the supply of blood to the heart muscle (myocardial…
- Trial name
- ASPECT (NCT00990327)
- Testing
- Apadenoson SPECT-MPI, Adenosine SPECT-MPI
- Where
- 122 sites in United States, Brazil
- Volunteers
- 863 people
- Sponsor
- Forest Laboratories
Coronary Artery Disease
Acquiring Consensus for Contrast Echocardiography System Settings - ACCESS Study
This study evaluated and optimized settings for, and evaluated the performance of, AI-700-enhanced echocardiographic imaging on several ultrasound imaging platforms, as well as collected additional safety data for AI-700 in…
- Trial name
- NCT00669851
- Testing
- AI-700
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Acusphere
Coronary Artery Disease, Healthy
Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems
The purpose of this clinical trial is to evaluate various commercially available ultrasound systems and to identify imaging parameters to be used with these systems (along with the contrast agent PB127) as well as to further…
- Trial name
- NCT00487903
- Testing
- PB127 for Injectable Suspension
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Point Biomedical
Coronary Artery Disease
Phase 3 Imaging and Safety Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing SPECT Imaging
This study was designed to evaluate the ability of AI-700-enhanced rest-stress echocardiography to detect coronary artery disease (CAD) in patients with suspected ischemic heart disease who are indicated for single-photon…
- Trial name
- NCT00156793
- Testing
- AI-700 contrast-enhanced echocardiography
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Acusphere
Coronary Artery Disease
A Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging
The purpose of this study is to determine how well perfusion cardiac magnetic resonance (MR) imaging is able to detect certain heart abnormalities, such as a coronary artery narrowing.
- Trial name
- MR-IMPACT-II (NCT00977093)
- Testing
- Perfusion CMR for detection of coronary artery disease, Perfusion cardiac magnetic resonance imaging
- Volunteers
- 533 people
- Sponsor
- Amersham Buchler, GmbH & Co KG
Healthy, Coronary Artery Disease
Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease
The purpose of this study is to determine the dose of PB127 for detection and/or exclusion of coronary artery disease when used with cardiac ultrasound. This study also evaluates the safety of PB127.
- Trial name
- NCT00584818
- Testing
- PB127 for Injectable Suspension
- Where
- 16 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Point Biomedical
Myocardial Perfusion Imaging, Diagnostic Certainty
Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis
Compare the diagnostic certainty of MIBI SPECT myocardial perfusion imaging (MPI) and XTR004 PET MPI.
- Conditions
- Myocardial Perfusion Imaging, Diagnostic Certainty, Stable Coronary Artery Disease
- Trial name
- NCT07187895
- Testing
- XTR004
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Sinotau Pharmaceutical Group